AI scans 3000 liver cancer patients to pick best therapy

NCT ID NCT07368530

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study analyzed medical images and data from 3000 patients with advanced liver cancer that cannot be removed by surgery. Researchers used an AI technique called radiomics to see if they could identify which patients would respond better to one of two standard treatments: TACE (a procedure that blocks the tumor's blood supply) or HAIC (chemotherapy delivered directly to the liver). The goal is to develop a tool that helps doctors personalize treatment decisions, but because this is a retrospective study looking at past data, it cannot prove that the AI model will work for future patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the best liver cancer treatment for each patient, improving outcomes without a one-size-fits-all approach.
What could go wrong
This is a retrospective study, meaning it looks back at old data, so it cannot prove cause and effect. The AI model may not work as well in new patients or other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCLC STAGE B HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiiated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.